Message from the Editor-in-Chief

International Journal of Translational Medicine (ISSN 2673-8937) is an international, peer-reviewed, open access journal that welcomes submissions from researchers, clinicians, policymakers, and the industry. It publishes reviews, regular research papers, short communications, and case reports. There is no restriction on the maximum length of the papers. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible. Full experimental and/or methodological details must be provided for research articles.

Author Benefits

- **Open Access** Unlimited and free access for readers
- **No Space Constraints, No Extra Space or Color Charges** No restriction on the maximum length of the papers, number of figures or colors
- **Rapid Publication** First decision provided to authors approximately 25.9 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2022)
Aims and Scope

The Aim and Scope of the *International Journal of Translational Medicine* (ISSN 2673-8937) is to promote the publication of research articles, special research topics, and review articles that can stimulate communication between basic and clinical scientists. The ultimate aim of the journal is to provide space to those studies that start from a clinical question, address it by transitioning to the bench, and then translate the solution to the bedside once the original clinical question is solved. The journal favors those studies and clinical observations that are generated by clear hypotheses-driven questions, which are disease-oriented, and which guide the investigations. The journal emphasizes the clinical applicability of new biomaterials, biotechnologies, bioengineering, biomarkers, diagnostics, omics science, molecular medicine, bioinformatics, immunology, molecular imaging, drug discovery and development, population health, infectious disease, gene therapy, stem cells, cancer, cancer stem cells, and cardiovascular disease. The *International Journal of Translational Medicine* welcomes submissions from researchers, clinicians, policymakers, and the industry. The scientific scope of this journal includes but is not limited to the following: publishing scientific articles that focus on preclinical research that has a high potential to transition to human therapies or on information directly derived from human experimentation with the intent to facilitate the communication between basic and clinical science.
MDPI is a member of

Follow

facebook.com/MDPIOpenAccessPublishing
twitter.com/MDPIOpenAccess
linkedin.com/company/mdpi
instagram.com/mdpiopenaccess
weibo.com/mdpicn
Wechat: MDPI-China

Subscribe

blog.mdpi.com

Visit.mdpi.com for a full list of offices and contact information.
MDPI is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3, whose registered office is at St. Alban-Anlage 66, CH-4052 Basel, Switzerland.